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Infectious diseases are indeed a lifelong threat to everyone irrespective of age, sex,
lifestyle and socio-economic status. The infectious diseases have persisted among the
prominent causes of death globally. Recently, re-emergence of Chikungunya viral
infection harmed many in Asian and African countries. Chikungunya was considered as a
major threat in developing and under-developed countries; the recent epidemiological
outbreak of Chikungunya in La Reunion urges the global researchers to develop effective
vaccine against this viral disease. In this review, Chikungunya, pathogenesis and
epidemiology were brieﬂy described.1. Introduction
Since the evolution of human race, infectious diseases also
have made headway. Even with the rapid development of
modern health care systems like usage of synthetic or recom-
binant drugs, we are still a step backward to nature, as some new
diseases occur time-to-time challenging the humanity. An in-
fectious disease is deﬁned as a clinically manifest infection,
resulting due to the pathogenic microorganisms, normally
illustrated as contagious (communicable) having ability to
transform from one person/species to other through physical
contact or it may be vector-borne or air-borne. Even though
many medical advances have been made during the past two
decades of the 20th century, there are still new and re-emerging
diseases, adding up with the massive spread of antibiotic resis-
tant pathogens and disease carrying insects that are resistant to
insecticides, are still scary challenge to human health. Still it is a
nightmare situation for public health system due to the emer-
gence of new diseases and also the re-emergence of old ones.Emerging and re-emerging infectious diseases may occur
anywhere across the world and its effect will be severe and
unpredictable. Advancement in the ﬁeld of medicine during the
past few decades made to believe that the infectious diseases are
under the control of humankind. Recently, re-emergence of old
infectious diseases debilitated many people globally. Re-
emerging diseases are already identiﬁed diseases that have
come back after a signiﬁcant delay in incidence. Some epidemic
diseases spread from one continent to another that affects the
country's economy and livelihoods. Global food trade is one of
the major factors that cause the infectious diseases to ﬂourish
across the world. Many emerging human diseases originate from
animals and transmitted to humans i.e., zoonosis. It has been
reported that the 75% of emerging and re-emerging pathogens
are zoonotic [1]. The zoonotic emerging infectious diseases
threaten humans as well as animal health. Much attention is
given to the zoonotic infectious diseases because of their
potential to transmit from animals to humans and also from
human to human transmission way. The areas rich in wildlife
are always the hotspots for most of the zoonotic diseases [2].
Infectious diseases are potentially contagious caused by mi-
croorganisms. Virus that has RNA as genetic material causes most
of the infectious diseases. The great impact of RNA viruses in
causing diseases are due to the fact that they are easily adapt to the
varying environmental conditions because of the high error rates of
the virus enzymes (RNA polymerases) that replicate their ge-
nomes, which doesn't have proof reading activity [3]. However, a
complex interplay of factors can inﬂuence disease emergencender the CC BY-NC-ND license (http://
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environmental factors like social and health care [4].
2. Tropical countries and infection
Historically contagious diseases hit the tropical regionsmore as
compared to the temperate regions. The most common disease
carrying vectors are mosquitoes and arthropods [5]. Human
movement is one of the key factors that inﬂuence the exposure
to vectors and the transmission of pathogens. Normally, the
outbreaks of many human diseases in the tropical region occur
during the wet season than in the dry season. The major reason
being the disease vectors, like mosquitoes and ﬂies are more
abundant during the wet season [6]. Mosquito is one of the major
disease causing vectors that spreads worldwide. In tropics, it is
impossible to avoid the omnipresence of mosquito and its bite
where mosquitoes and humans co-exist. Even though there are
more repellents exist commercially, none seems to be effective
against these lean mean-biting machines. Frequently female
mosquito is the one, transmitting the diseases since the blood meal
is obligatory for the mosquitoes in order to lay eggs. For laying
eggs, mosquitoes mostly prefer freshwater, some species prefer
brackish water [7]. The larvae from the eggs release into the water,
where they complete their larval life cycle and emerge as adult
mosquitoes. The most dreaded infections caused by mosquitoes
are mainly Malaria, Dengue and Chikungunya.
3. Chikungunya
The word Chikungunya (CHIK) is used to represent both the
virus and disease. Chikungunya virus (CHIKV) is an arthropod
borne virus, belongs to the family Togaviridae and genus Alpha-
virus, which is responsible for Chikungunya fever in humans [8].
CHIKV believed to be originated from Africa and subsequently
transferred to Asia. CHIKV infection was ﬁrst reported in
Tanzania in 1952 and ﬁrst isolated in 1953 [9]. Chikungunya is a
word meaning ‘The bent walker/stooped walk’ referring to the
posture of the affected patient acquired due to unbearable pain in
the joints and other rheumatologic complications [10]. CHIKV is
geographically distributed in tropical and sub-tropical regions of
many Asian and African countries. The virus was commonly
transmitted by arthropods like mosquitoes Aedes aegypti
(Ae. aegypti) and Aedes albopictus (Ae. albopictus), where it is
maintained in ‘sylvatic cycle’ but the common reservoirs for the
virus are monkeys and other vertebrates [11]. Mainly humans are
the reservoirs for the Chikungunya virus (Urban Cycle) during
epidemic period. Thus, alphavirus are maintained in mosquito
vectors and vertebrate hosts. Phylogenetic analysis revealed that
there are 3 different CHIKV isolates i.e., West African and East
Central South African and Asian genotypes with distinct
antigenic and genotypic characteristics [12]. Due to the serious
risk imposed by Chikungunya on humans, it was categorized as
a category C priority pathogen by US National Institute of
Allergy and Infectious Diseases in 2008 [13].4. CHIK virion structure
Alphaviruses are membrane enveloped viruses, which con-
sists of a single-stranded RNA as a genetic material and an
icosahedral like nucleocapsid of size (60–70) nm diameter [14].
The alphavirus genome consists of single-stranded, positivesense RNA of about 11.8 kb with a 50 cap structure and 30
polyadenosine tail [9].
CHIKV contains two open reading frames (ORF) that code
for structural and non-structural proteins. The amino acid
sequence identity between CHIK and other alphavirus range
from 58% to 85% and 42%–85% in case of non-structural and
structural proteins, respectively [9]. Non-structural polyproteins
(nsP1-4) are synthesized directly from the sub-genomic RNA
that is essential for viral replication and processing. The junction
region between two ORF is untranslatable composed of 68 bp
that contains an internal promoter and start site for the tran-
scription of sub-genomic RNA. The nonstructural proteins are
mainly involved in viral pathogenesis by interacting with viral
and host cell components [8].
All the structural proteins such as capsid, E1, E2, E3 and 6K
are produced from the 26S sub-genomic RNA as a single poly-
peptide, which undergoes cleavage and post-translational modi-
ﬁcations to form major three proteins capsid, E2, E1 and two
minor proteins E3 and 6K that are involved in viral encapsidation
and budding [15]. The CHIKV envelope protein E1 consists of
435 amino acids (45 kDa) which are largely covered by E2 in
the viral envelope. Similar to E1, pE2 protein (65 kDa) is the
type I transmembrane glycoproteins, which is the precursor for
E3 and E2 proteins that undergoes post-translational modiﬁca-
tion to form E2 and E3 proteins. pE2 and E1 glycoproteins form
heterodimers in the endoplasmic reticulum (ER), then E3 is
cleaved from pE2 by furin in the golgi complex that eventually
forms the E1–E2 heterodimers and later develop as spike on the
virus envelope [16]. E2 protein belongs to the immunoglobulin
super gene family that has three regions; ectodomain (260
amino acids), stem region (100 amino acids) and
transmembrane helix. About 33 amino acids present in
carboxy-terminal domain of E2 interact with the nucleocapsid
core, which drives the budding process. E3 protein is a small a/b
protein consists of 64 amino acids (11 kDa) that have disulﬁde
isomerase activity helps in proper folding and disulﬁde bond
formation in the viral glycoproteins. CHIKV 6K is small, hy-
drophobic protein essential for the viral particle assembly, which
acts as a signal sequence for the processing of E1 protein [15,17].
The role of 6K protein in viral replication is not fully resolved.
Capsid protein is 261 amino acids (30 kDa) long, expressed
as a part of structural polyprotein, which has conserved auto-
protease domain in the C-terminal end that helps to release itself
from the polypeptide string after synthesis of structural proteins
[18]. The capsid is surrounded by a lipid bilayer derived from the
plasma membrane of host cell in which almost 240 copies of E1
and E2 heterodimers in turn assembled into trimers (80 Copies)
are embedded and forms the rigid structure across the membrane
[19]. These envelope glycoproteins help in the attachment of
viruses to the host cell during infection.
5. Replication of alphavirus
The envelope glycoprotein present on the surface of the
viral capsid interacts with the membrane bound receptors and
enters into the host cell by receptor mediated endocytosis [15].
The cell surface receptors like ICAM-3 grabbing non-integrin
and laminin like receptors have been reported for other
alphavirus, but for CHIK, no cell surface receptors have been
identiﬁed both in mosquito and humans till date [8]. However,
it was also reported that some viruses utilize clathrin dependent
and caveolin dependent pathways for cellular entry [20,21]. The
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fusion of virus into the host cell. Inside the endosomes, the
conformational change of E1-E2 heterodimer occurs, which
is mediated by low pH that exposes the furin peptide towards
the target membrane. The E2 protein has been responsible for
receptor binding during the course of viral infection and de-
livers the nucleocapsid along with viral RNA into the host
cytoplasm [16].
After entering the host cell cytoplasm, the capsid protein
binds to large ribosomal sub-units and releases the viral RNA.
The viral genome is then translated from two open reading
frames to produce non-structural and structural polyproteins [22].
The N-terminal ORF encodes a nonstructural polyprotein of
2474 amino acids, nsP123 and nsP4. This precursor nsP123 is
proteolytically cleaved and forms nsP1, nsP2, nsP3 and then
join with nsP4. A leaky termination codon was observed in
most of the alphavirus genome after nsP3; hence the protein
synthesis occurs at 10%–20% efﬁciency that eventually leads
to an excess of nsP123 than nsP1234. Hence, nsP4 is
relatively low when compared to other nsPs. Furthermore,
nsP4 is stable in the form of replication complex and degraded
when it is in excess [23,24].
After the synthesis of non-structural polyproteins, it forms
the replication complex within virus induced cytopathic vacu-
oles (CPVⅠ) and initiates positive strand genomic and sub-
genomic RNA synthesis [15,25]. The sub-genomic RNA (26S)
translates and produces viral structural polyprotein (1244 amino
acids). After synthesis, capsid protein is cleaved off from the rest
of the structural polyproteins due to its auto-proteolytic cleavage
activity. The capsid protein recognizes the speciﬁc packaging
signals in the 50 half of the genome and packed with the RNA
genome to form nucleocapsid [26]. The N-terminal signal
sequence of E3 protein directs the remaining polyprotein to
the endoplasmic reticulum, where it is processed by host
signal peptidase. Similarly small 6K peptide acts as a signal
sequence for the E1 protein processing. After modiﬁcation, E1
protein interacts with pE2 (E3 + E2), thereby forming the
heterodimers and transported via, golgi complex [16,27]. At the
late stage of transport, pE2 is cleaved by host furin like
protease, which eventually weakens the E1 and E2
heterodimer priming the exposure and activation of fusion
peptide at the time of low pH exposure [8]. On the virion
surface, E1 and E2 are closely paired and together form
trimers that appear as ‘spikes’. Then the fully assembled
virion particles acquire the lipid bilayer from the host cell
plasma membrane and ﬁnally released from the host cell by
budding process [28].
6. Vectors for CHIKV
Mosquitoes are the common vectors for most of the arbovirus
and it is responsible for the 5 major diseases in India viz., Ma-
laria, Filaria, Dengue, Chikungunya and Japanese Encephalitis.
Ae. albopictus and Ae. aegypti is the major culprit for Chi-
kungunya disease. Though Ae. aegypti is the primary classical
vector for CHIKV, both the species is known to be susceptible to
CHIKV infection. Ae. albopictus was responsible for the 2005–
2006 Chikungunya epidemic in Reunion island and identiﬁed as
a major vector in Europe, whereas Ae. aegypti is the dominant
CHIKV carrier in India [29].
Aedes mosquitoes are known to be important vector for
dengue and other arbovirus [30]. Ae. albopictus easily adapts inboth the rural and urban environments that makes it a ideal
viral vector. Besides, the mosquito's eggs are highly resistant
even in dry period, giving rise to larvae in rainy season. All of
these characters make Ae. albopictus, an important vector for
spreading this disease. Ae. albopictus is geographically
distributed in Asia, Europe, Middle East and America [29].
Thus worldwide urbanization and expanding geographical
range of Aedes mosquitoes have driven the rise in
Chikungunya infections globally. During the epidemic period,
human beings act as reservoirs for the Chikungunya virus,
whereas the major reservoirs are mosquitoes, rodents and birds
[31]. Till now, there is no existing vaccine or speciﬁc treatment
available to treat Chikungunya infection.7. Outbreaks of Chikungunya
Chikungunya become a disease of global distress following
its recent revitalization. The possible factors that inﬂuence the
re-emergence of CHIKV include, immunologically compro-
mised human population, global trade, international travel and
most importantly the adaptation of the virus to anthropophilic
Asian tiger mosquito (Ae. albopictus) [32]. After the ﬁrst report
from Tanzania in 1952, Chikungunya epidemics have been
reported in major parts of Africa and Asia, in particular
Southeast Asia, India, Pakistan, Sri Lanka, Myanmar, Thailand
and in many islands of the Paciﬁc Ocean like Madagascar,
Mauritius and the Reunion Island (Indian Ocean) [33]. In 1958,
CHIKV was reported in Asia for the ﬁrst time in Bangkok
[34]. In 1963, Chikungunya ﬁrst made its headway in India
(Kolkata), followed by Pondicherry and Vellore (1964),
Visakhapatnam, Rajmundry and Kakinada (1965), Nagpur
(1965) and Barsi (1973) [35].
From 1973 to 2005, no cases were reported in India. In 2006,
Chikungunya suddenly re-emerged as a major outbreak in India
after 32 years. Over 1400000 cases were reported during the
outbreak [31]. Since 2005, several states in India experienced
massive outbreaks of epidemic that badly affects the many
people. In 2005–2006, Chikungunya hit Andhra Pradesh and
Tamil Nadu, India, which was the recent major outbreak. The
major complaint during that outbreak was high fever and
crippling joint pain. In recent past (2007), Chikungunya
outbreak in French La Reunion island, where mortality was
reported and almost one third of the population (35%) was
affected by Chikungunya fever [36,37].
After which, Chikungunya has been identiﬁed in almost 40
countries including Indonesia, Thailand, Malaysia, Philippines
the Indian Ocean islands of Mayotte, Seychelles, Mauritius and
La Reunion. Before the Chikungunya outbreak in Italy, the
major question in 2007 was ‘When and where the next Chi-
kungunya epidemic’ will re-occur? At that time the probable
answer was tropical and sub-tropical countries. But after the
outbreak in Italy, the risk imposed by Chikungunya was severe
threat for both temperate and tropical world.8. Symptoms and signs
After the CHIKV infected Ae. aegypti or Ae. albopictus
mosquitoes bite humans, viruses start its multiplication in the
human body that eventually causes arthralgic syndrome/Chi-
kungunya fever. During epidemics, the attack rate was >50%
and almost two thirds of the infected patients had to be
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but mortality was also reported in recent outbreaks in India,
Italy and La Reunion [40]. Symptoms of Chikungunya fever
were similar like dengue and often it is clinically difﬁcult to
distinguish from the dengue or O'nyong–nyong infection,
which accounts for misclassiﬁcation [8]. The major symptoms
of CHIKV infection include fever, headache and joint pains/
polyarthralgia that last for several days to months and the
fatality was rare in most cases; whereas tenosynovitis,
myalgia, headache, nausea, vomiting, lymphadenopathy,
asthenia and dysgeusia were also reported in few patients
[41,42]. After the infected mosquito bites the human, the virus
starts replication and distributes to the liver/joints and damages
the collagen and disrupts the connective tissue metabolism
leads to acute arthritis [43]. The latent period for CHIKV
normally ranges from (2–12) days. Usually CHIKV infection
appears to be mostly symptomatic but asymptomatic infection
was also reported in 3%–25% of people [44].
9. Diagnosis, treatment and prevention
Chikungunya virus can be diagnosed by viral culture but the
facilities needed for culturing the viruses are not widely avail-
able in many underdeveloped and developing countries. Mo-
lecular tools such as RT-PCR and serodiagnostic methods like
Enzyme-linked immunosorbent assay, indirect immunoﬂuores-
cent method, hemagglutination inhibition, or neutralization
techniques for the detection of IgM and IgG antibodies against
Chikungunya virus in sera can also be used [31,45].
Currently there is no anti-viral therapy available to inhibit
viral replication during human infection; hence the infected
patients are given analgesics, anti-inﬂammatory drugs and
paracetamol [46] to reduce the viremia symptoms. Taking non-
steroidal anti-inﬂammatory drugs may reduce the symptoms of
fever and pain [31]. Apart from this, vector control measures are
recommendable that would probably reduce the density of
Ae. aegypti/Ae. albopictus.
10. Current status of CHIKV vaccines
Several groups around the world are working on to develop
CHIK vaccines using various strategies including inactivated
viral vaccines, live-attenuated viruses, chimeric viruses, recom-
binant viral vaccines, consensus-based DNA vaccines, recom-
binant subunit vaccines and more recently, a virus-like particle
vaccine [47–51]. The ﬁrst live attenuated vaccine was reactogenic
in clinical trials and chimeric alphavirus by employing structural
protein showed good promise for CHIKV prevention in pre-
clinical trials [52]. A virus like particle vaccine expressing
Chikungunya polyprotein induced high antibody titres and
protects monkeys from CHIKV infection after challenge [47].
A DNA vaccine based on Chikungunya envelope proteins
elicit high neutralizing antibody titres and protected the mice
from intranasal CHIKV challenge [48].
11. Conclusions
Chikungunya is a re-emerging disease which affects many
people at regular intervals. However the clinical features and
number of affected people are keep on increasing compared to
its previous outbreak. The proper control measures andpreventive strategies are essential to prevent this epidemic. The
recent outbreak of Chikungunya has affected many countries
and hence it is essential that researchers develop vaccine to
control this disease. Still there is no anti-viral treatment, how-
ever many vaccines are in development or clinical trials. The
collaboration of several researchers might helpful to develop an
effective treatment against this infection.
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